Facebook Pixel Powell says Fed doesn't need to rush on rate cuts | Mint Chennai - newspaper - Lees dit verhaal op Magzter.com
Ga onbeperkt met Magzter GOLD

Ga onbeperkt met Magzter GOLD

Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts

$149.99
 
$74.99/Jaar

Poging GOUD - Vrij

Powell says Fed doesn't need to rush on rate cuts

Mint Chennai

|

February 13, 2025

Fed chair outlines paths for 2025: Hold rates if inflation doesn't improve or cut if economy slows more sharply

- Nick Timiraos

Federal Reserve Chair Jerome Powell delivered a simple message to Congress to start two days of testimony on Tuesday: Because the economy is doing well, the Fed can take its time to decide when and whether to lower interest rates.

"We're in a pretty good place with this economy. We want to make more progress on inflation. And we think our policy rate is in a good place, and we don't see any reason to be in a hurry to reduce it further," Powell told members of the Senate Banking Committee.

The central bank cut interest rates at its last three meetings of 2024 by a full percentage point after holding rates near a two-decade high. Powell defended last year's rate cuts as a needed recalibration of the Fed's policy stance to account for improvement on inflation and cooler labor market conditions.

Powell received minimal pushback from senators over recent interest-rate moves. That is despite criticism from some Republicans who last year accused the Fed of being politically motivated in cutting rates and some Democrats who said rates were too high.

One Republican lawmaker, Sen. John Kennedy of Louisiana, patted Powell on the back for achieving what is called a soft landing that has brought inflation down without a meaningful increase in unemployment.

MEER VERHALEN VAN Mint Chennai

Mint Chennai

Mint Chennai

Barrier-free tolling runs into a Chinese camera security bump

Commuters looking to zoom past toll plazas on India's 146,560 km highway network will have to wait longer.

time to read

1 min

February 26, 2026

Mint Chennai

A new grammar to challenge Tamil film

Members of the Problematic Family, which premiered at the Berlinale, is a striking, experimental debut film from R. Gowtham

time to read

3 mins

February 26, 2026

Mint Chennai

AUROBINDO PHARMA TAKES A PENICILLIN SHOT

The company has made a ₹2,500 crore bet to rebuild its antibiotic backbone. Will it work?

time to read

6 mins

February 26, 2026

Mint Chennai

Digital rupee pilot for food subsidy

In a significant shift in the way food subsidies are delivered, the government will launch a central bank digital currency (CBDC)-based pilot under the Pradhan Mantri Garib Kalyan Anna Yojana (PMGKAY) in Puducherry on 26 February.

time to read

1 min

February 26, 2026

Mint Chennai

DRL's obesity jab may launch in March

Dr. Reddy's Laboratories (DRL) is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, according to two people familiar with the matter as well as images reviewed by Reuters.

time to read

1 min

February 26, 2026

Mint Chennai

Mint Chennai

Uranium supply deal likely during Carney’s India visit

Cameco CEO Tim Gitzel to be part of the business delegation accompanying Canadian PM

time to read

2 mins

February 26, 2026

Mint Chennai

Mint Chennai

Warner interested in Paramount offer

Warner Bros Discovery Inc. said a new $31-a-share buyout offer from Paramount Skydance Corp. could lead to a better deal than its existing agreement with Netflix Inc., kicking off another potential round of bidding for the famed Hollywood studio.

time to read

1 mins

February 26, 2026

Mint Chennai

Mint Chennai

Hype and havoc shroud Al's impact on IT firms

Is investor anxiety over the business models of IT service companies being rendered obsolete by AI overblown? The truth lies between an apocalypse and AI-impact denial. Here's why

time to read

2 mins

February 26, 2026

Mint Chennai

Mint Chennai

Zydus plans obesity jab in pens after semaglutide patent ends

Ahmedabad-based drugmaker Zydus Lifesciences plans to launch its semaglutide injection brands upon patent expiry of the drug in India.

time to read

1 mins

February 26, 2026

Mint Chennai

Mint Chennai

CHASING 12% EQUITY RETURNS? LONG-TERM INVESTING ISN'T JUST ABOUT A NUMBER

Most investors enter equity mutual funds expecting an annual average return of about 12%.

time to read

3 mins

February 26, 2026

Listen

Translate

Share

-
+

Change font size